Estrella Immunopharma, Inc. · NASDAQ:ESLA
Estrella Immunopharma — Investor Presentation (March 2026)
27 slides from Estrella Immunopharma's investor presentation, March 2026
Slide 1: Corporate Presentation March 2026
Corporate Presentation March 2026
Slide 2: Disclaimer
Disclaimer Limitations Any reproduction or distribution of this Presentation, in whole or in part, or the disclosure of its contents, without the pr ior consent of Estrella Immunopharma, Inc. (“we,” “us,” “our” or the “Company”) is prohibited. By accepting this Presentation, each recipient agrees: (
Slide 3: Estrella is Well-Positioned to Significantly Expand Accessible Market of CD19-Targeting T-Cell Therapy
Estrella is Well-Positioned to Significantly Expand Accessible Market of CD19-Targeting T-Cell Therapy • $3.7B1 combined sales in 2025 7% • 80,3502 newly diagnosed Non-Hodgkin Approved CD-19 Lymphoma (NHL) patients and 772,9763 Targeted CAR-T Therapies prevalent cases in the US in 2025. However, onl
Slide 4: ARTEMIS T-cell Therapy is Designed to Address Major Limitations of Traditional CAR-T Therapies
ARTEMIS® T-cell Therapy is Designed to Address Major Limitations of Traditional CAR-T Therapies Traditional CAR-T Therapies Estrella ARTEMIS® T-cell Therapy Better safety profile and efficacy Safety Risks for Severe Cytokine Accessible for wider patient release syndrome (CRS) and population, such as
Slide 5: Leading the Development of Next-Generation CD19 Immunotherapy
Leading the Development of Next-Generation CD19 Immunotherapy A clinical-stage biopharmaceutical company developing T-cell therapies with the capacity to address treatment challenges for patients with cancers and autoimmune diseases. Our Mission Our Products Our Partnership • Lead product candidate,
Slide 6: Lead Product: EB103 (CD19-Redirected ARTEMIS T-Cell Therapy)
Lead Product: EB103 (CD19-Redirected ARTEMIS® T-Cell Therapy) 6
Slide 7: EB103 Targets Best-in-Class Safety and Efficacy Among CD19 CAR T-cell Therapies
EB103 Targets Best-in-Class Safety and Efficacy Among CD19 CAR T-cell Therapies Current Status 29 patients treated including high-risk patients, with favorable safety profile Efficacy Signal 100% CR in high-dose cohort in US Phase I. All patients who achieved CR remain in CR as of January 28, 2026.
Slide 8: STARLIGHT-1 (NCT06343311) Highlights: Early Promising Efficacy Signal
STARLIGHT-1 (NCT06343311) Highlights: Early Promising Efficacy Signal Observed in High-Dose Level STARLIGHT-1 STARLIGHT-1 ZUMA-1 JULIET TRANSCEND DL1* DL2** (Yescarta) (Kymriah) (Breyanzi) 3 Enrolled 6 Enrolled 119 Enrolled 167 Enrolled 344 Apheresed 3 Evaluable 5 Evaluable*** 108 Infused 115 Infuse
Slide 9: STARLIGHT-1 (NCT06343311) Highlights: Favorable Safety Profile
STARLIGHT-1 (NCT06343311) Highlights: Favorable Safety Profile Observed across Dose Levels Summary of Treatment-Related Adverse Events (TRAEs) in Phase 1 Patients Treated with EB103 • 80% of patients are considered high-risk patients including one PCNSL patient • EB103 T-cell therapy has been well t
Slide 10: EB103 Can Treat High-Risk Patient Groups Excluded by Current Approved CD19 CAR T Products
EB103 Can Treat High-Risk Patient Groups Excluded by Current Approved CD19 CAR T Products Current Approved CD19 CAR T Products EB103 Excluded from FDA approval: Patients with primary central nervous system lymphoma Included in FDA-approved Phase I/II trial: Patients with HIV- associated lymphoma and
Slide 11: FDA Black Box Warning for Approved CD19 CAR T Products Limits Access to Community Hospitals
FDA Black Box Warning for Approved CD19 CAR T Products Limits Access to Community Hospitals Current Approved CD19 CAR T Products EB103 LIMITED to a small number of specialized CAR T-capable medical centers* due to safety risks EXPAND availability to community FDA Black Box Warning: Highlights severe
Slide 12: Recent Buy Rating Reports
FfRecent Buy Rating Reports March 18, 2026 David Bautz, PhD 312-265-9471 dbautz@zacks.com Zacks Small-Cap Resea Sponsored — Impartial - Comprehensive 101 N. Wacker Drive, Chicago, IL 60606 (ESLA-NASDAQ) Scr.zacks.com Estrella Immunopharma, Inc. , INETIASTING COVER Health = Fel Initiation Equity Repo
Slide 13: EB103 in the US: Clinical Development and Value Inflection Point within 12 Months
EB103 in the US: Clinical Development and Value Inflection Point within 12 Months As of today $5-10 Billion Initiation of Registrational Trial Initiation of Phase II Completion 1H 2026 of Phase I (~20 patients) 1st patient 2H 2025 dosed (9 patients) First patient Sept 2024 enrollment IND July 2024 c
Slide 14: Unlocking Value: Significant Upside Market Cap Potential Compared to Phase I CD19 CAR T Peers
Unlocking Value: Significant Upside Market Cap Potential Compared to Phase I CD19 CAR T Peers Estrella is positioned to capture significant valuation upside 1,600 300 1,400 1,500 250 1,200 1,200 200 1,000 $ Millions 800 150 600 100 400 50 200 290 260 - - Poseida Gracell Estrella Market Cap Before M&
Slide 15: EB103 ARTEMIS T Cells
ESTRELLA EB103 ARTEMIS® T Cells 15
Slide 16: EB103 ARTEMIS T Cells
EB103 ARTEMIS® T Cells AbTCR CD19 CD19-Redirected Cancer Cell EB103 T Cell CD19 Co-stim EB103 CD19-Redirected ARTEMIS® T Cells Key Unit – AbTCR and Co-stim EB103 Engineered to express ARTEMIS ® cell receptors (i.e., the AbTCR and The key units of our novel, proprietary CD19-Redirected ARTEMIS® T Cel
Slide 17: Proprietary ARTEMIS Technology
Proprietary ARTEMIS® Technology ARTEMIS® Superiority to Conventional CAR-T ▪ ARTEMIS® T-cell therapy is clinically validated in patients ▪ ARTEMIS® vs. CAR-T* ✓ Superior efficacy ✓ Enhanced tumor infiltration ✓ Less T cell exhaustion ✓ Reduced Cytokine release syndrome (CRS) and cytokine related tox
Slide 18: Better Safety and Potent Anti-tumor Efficacy
Better Safety and Potent Anti-tumor Efficacy ▪ Collaboration research between Eureka Therapeutics, Inc., Estrella’s parent company, and Dr. Grupp’s team showed CD19 ARTEMIS® T-cell Therapy demonstrated better safety and anti-tumor efficacy. ▪ The research paper Xu et al. Cell Discovery (2018) 4:62 p
Slide 19: Preclinical Data Demonstrates Superior Safety/Efficacy Profile Compared to Yescarta
Preclinical Data Demonstrates Superior Safety/Efficacy Profile Compared to Yescarta CD19 ARTEMIS ® T cells release less CD19 ARTEMIS® T cells shows matching efficacy in CRS-related cytokines than CAR-T, including IL-6 mouse model (Raji) Mock CD19-CAR CD19 ARTEMIS® CAR-T ARTEMIS Xu et al., Cell Disco
Slide 20: EB103 Investigator-Initiated Study
EB103 Investigator-Initiated Study 20
Slide 21: Snapshots of Estrella CD19 Therapy in Lymphoma Patients
Snapshots of Estrella CD19 Therapy in Lymphoma Patients ▪ Collaboration research with the First Affiliated Hospital of Xi’an Jiaotong University for exploratory, single-arm, open-label, non- randomized early investigator initiated study (“IIS”). 2021 826 Novel CD19-Specific γ/δ TCR-T Cells in Relaps
Slide 22: EB103 Clinical Studies
EB103 Clinical Studies ▪ This IIS study (1) provides data that indicates that EB103 has anti-tumor activity and an attractive safety profile in patients with CD19-positive r/r B-cell lymphoma. (c) Representative radiographic images of two responders (BH05-P10 and (a) Treatment response and duration
Slide 23: EB103 Clinical Studies
EB103 Clinical Studies ▪ This IIS study (1) provides data that indicates that EB103 has anti-tumor activity and an attractive safety profile in patients with CD19-positive r/r B- cell lymphoma. ➢ The study enrolled patients from November 2018 to January 2020 (1) 16 patients were enrolled, and 12 pat
Slide 24: Estrella Leadership
ESTRELLA BIOPHARMA Estrella Leadership 24
Slide 25: Dr. Cheng Liu Founder of Estrella and Eureka
Dr. Cheng Liu Founder of Estrella and Eureka • Over 30 years of experience in the field. • Holds more than 500 patents and published patent applications of which over 100 patents have issued worldwide. Cheng Liu, PhD • Inventor of multiple first-in-class, clinical-stage cancer drugs Founder, against
Slide 26: Estrella's Scientific Advisory Board Includes World-Class Thought Leaders
Estrella’s Scientific Advisory Board Includes World-Class Thought Leaders David Scheinberg, Stephan Grupp, Randy Schekman, MD, PhD MD, PhD PhD • Physician, scientist, drug developer, • Chief of the Cell Therapy and Transplant • Cell Biologist at UC Berkeley entrepreneur, and pioneer of targeted Sect
Slide 27: Eureka Therapeutics - Pioneer in the Field of T-cell Therapy
Eureka Therapeutics - Pioneer in the Field of T-cell Therapy Proprietary ARTEMIS® technology empowering Headquartered in San Francisco Bay Area T-cells to infiltrate solid tumors In-house Human Antibody Discovery Platform Strong pipeline with multiple Clinical Programs currently in Phase I/II trials
Estrella Immunopharma — Investor Presentation (March 2026) on 6ix